Generative AI is rapidly revolutionizing the field of biotechnology. It is streamlining the design of drug compounds digitally and enhancing precision medicine through comprehensive genomic and clinical evaluations. The global market for AI in biotechnology is projected to nearly double by 2031, fueled by advanced simulations, NLP-driven knowledge graphs, and swift clinical validation. North America is at the forefront, with Asia-Pacific gaining momentum. The biotech revolution is underway — and AI is altering every standard.
Comments